Muscle damage is linked to cytokine changes following a 160-km race
Muscle damage and perceived soreness following the 160-km Western States Endurance Run were related to changes in plasma cytokines and use of nonsteroidal anti-inflammatory drugs (NSAIDS). Subjects included 60 ultramarathoners (mean ± SE, age 45.3 ± 1.1 years) who finished the race in under 30 h (26...
Gespeichert in:
| Veröffentlicht in: | Brain, behavior, and immunity behavior, and immunity, 2005-09, Vol.19 (5), p.398-403 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 403 |
|---|---|
| container_issue | 5 |
| container_start_page | 398 |
| container_title | Brain, behavior, and immunity |
| container_volume | 19 |
| creator | Nieman, David C. Dumke, Charles L. Henson, Dru A. McAnulty, Steven R. Gross, Sarah J. Lind, Robert H. |
| description | Muscle damage and perceived soreness following the 160-km Western States Endurance Run were related to changes in plasma cytokines and use of nonsteroidal anti-inflammatory drugs (NSAIDS). Subjects included 60 ultramarathoners (mean
±
SE, age 45.3
±
1.1 years) who finished the race in under 30
h (26.3
±
0.4
h). Blood samples were collected the morning prior to and immediately following the race, and subjects recorded muscle soreness during the week following the race using a 10-point Likert scale (DOMS). Seven plasma cytokines were measured including IL-6, IL-10, IL-8, IL-1ra, granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β). Cytokine changes were compared between NSAID users and nonusers, and correlated with creatine phosphokinase (CPK) and DOMS. Significant increases were measured for all seven cytokines, with the greatest fold increases seen for IL-6 (125×), IL-10 (24×), and G-CSF (12×). CPK was correlated with changes in IL-6, G-CSF, IL-10, IL-1ra, and MCP-1 (
r
=
.49–.68), (
P
<
.001), but not IL-8 or MIP-1β. DOMS averaged 7.1
±
0.3 the day after the race, and 5.0
±
0.3, 2.5
±
0.2, and 1.6
±
0.1 3 days, 5 days, and 7 days post-race, respectively, and each was correlated with CPK (
r
=
.40–.63,
P
<
.001) and changes in IL-6, G-CSF, IL-10, and MCP-1 (
r
=
.28–.77,
P
<
.05). A comparison of NSAID users (72% of athletes) and nonusers showed no differences in CPK or DOMS, but did reveal greater increases in five of seven cytokines in the NSAID users (
P
<
.05). In conclusion, muscle damage in athletes competing in a 160-km race was significantly correlated with post-race DOMS and increases in five of seven cytokines. NSAID users did not experience a reduction in muscle damage or DOMS, but did have higher post-race plasma levels in five of seven cytokines. |
| doi_str_mv | 10.1016/j.bbi.2005.03.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68441487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S088915910500053X</els_id><sourcerecordid>68441487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-9c3e9ec5b2c406471e63d5898d8b42b33a908c25eb92fb9a66d6efa5daac0c123</originalsourceid><addsrcrecordid>eNqFkDtPwzAURi0EouXxA1iQJ7aEe-PEtcWEKl4SiAVmy7Fvits8IE5B_HtStRIbTN9yvjMcxs4QUgSUl8u0LEOaARQpiBRA7bEpgoYkQ6H32RSU0gkWGifsKMYljKBAdcgmKEEi5nrK5k_r6Gri3jZ2QTxEXod2RZ4PHXffQ7cKLXH3ZtsFRV51dd19hXbBLR8VyarhvXV0wg4qW0c63e0xe729eZnfJ4_Pdw_z68fECZUNiXaCNLmizFwOMp8hSeELpZVXZZ6VQlgNymUFlTqrSm2l9JIqW3hrHTjMxDG72Hrf--5jTXEwTYiO6tq21K2jkSrPMVezf0GciVyrQowgbkHXdzH2VJn3PjS2_zYIZpPYLM2Y2GwSGxBmTDx-znfyddmQ_33smo7A1RagscVnoN5EF6h15ENPbjC-C3_ofwBZPoqO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17349853</pqid></control><display><type>article</type><title>Muscle damage is linked to cytokine changes following a 160-km race</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Nieman, David C. ; Dumke, Charles L. ; Henson, Dru A. ; McAnulty, Steven R. ; Gross, Sarah J. ; Lind, Robert H.</creator><creatorcontrib>Nieman, David C. ; Dumke, Charles L. ; Henson, Dru A. ; McAnulty, Steven R. ; Gross, Sarah J. ; Lind, Robert H.</creatorcontrib><description>Muscle damage and perceived soreness following the 160-km Western States Endurance Run were related to changes in plasma cytokines and use of nonsteroidal anti-inflammatory drugs (NSAIDS). Subjects included 60 ultramarathoners (mean
±
SE, age 45.3
±
1.1 years) who finished the race in under 30
h (26.3
±
0.4
h). Blood samples were collected the morning prior to and immediately following the race, and subjects recorded muscle soreness during the week following the race using a 10-point Likert scale (DOMS). Seven plasma cytokines were measured including IL-6, IL-10, IL-8, IL-1ra, granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β). Cytokine changes were compared between NSAID users and nonusers, and correlated with creatine phosphokinase (CPK) and DOMS. Significant increases were measured for all seven cytokines, with the greatest fold increases seen for IL-6 (125×), IL-10 (24×), and G-CSF (12×). CPK was correlated with changes in IL-6, G-CSF, IL-10, IL-1ra, and MCP-1 (
r
=
.49–.68), (
P
<
.001), but not IL-8 or MIP-1β. DOMS averaged 7.1
±
0.3 the day after the race, and 5.0
±
0.3, 2.5
±
0.2, and 1.6
±
0.1 3 days, 5 days, and 7 days post-race, respectively, and each was correlated with CPK (
r
=
.40–.63,
P
<
.001) and changes in IL-6, G-CSF, IL-10, and MCP-1 (
r
=
.28–.77,
P
<
.05). A comparison of NSAID users (72% of athletes) and nonusers showed no differences in CPK or DOMS, but did reveal greater increases in five of seven cytokines in the NSAID users (
P
<
.05). In conclusion, muscle damage in athletes competing in a 160-km race was significantly correlated with post-race DOMS and increases in five of seven cytokines. NSAID users did not experience a reduction in muscle damage or DOMS, but did have higher post-race plasma levels in five of seven cytokines.</description><identifier>ISSN: 0889-1591</identifier><identifier>EISSN: 1090-2139</identifier><identifier>DOI: 10.1016/j.bbi.2005.03.008</identifier><identifier>PMID: 16061149</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Blood Cell Count ; Blood Volume - physiology ; Body Composition - physiology ; Creatine Kinase - blood ; Cytokines - blood ; Female ; Humans ; IL-10 ; IL-1ra ; IL-6 ; IL-8 ; Lymphocyte Subsets ; Male ; Middle Aged ; Muscle soreness ; Muscle, Skeletal - metabolism ; Muscle, Skeletal - pathology ; NSAIDs ; Physical Endurance - physiology ; Running - physiology</subject><ispartof>Brain, behavior, and immunity, 2005-09, Vol.19 (5), p.398-403</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-9c3e9ec5b2c406471e63d5898d8b42b33a908c25eb92fb9a66d6efa5daac0c123</citedby><cites>FETCH-LOGICAL-c382t-9c3e9ec5b2c406471e63d5898d8b42b33a908c25eb92fb9a66d6efa5daac0c123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S088915910500053X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16061149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nieman, David C.</creatorcontrib><creatorcontrib>Dumke, Charles L.</creatorcontrib><creatorcontrib>Henson, Dru A.</creatorcontrib><creatorcontrib>McAnulty, Steven R.</creatorcontrib><creatorcontrib>Gross, Sarah J.</creatorcontrib><creatorcontrib>Lind, Robert H.</creatorcontrib><title>Muscle damage is linked to cytokine changes following a 160-km race</title><title>Brain, behavior, and immunity</title><addtitle>Brain Behav Immun</addtitle><description>Muscle damage and perceived soreness following the 160-km Western States Endurance Run were related to changes in plasma cytokines and use of nonsteroidal anti-inflammatory drugs (NSAIDS). Subjects included 60 ultramarathoners (mean
±
SE, age 45.3
±
1.1 years) who finished the race in under 30
h (26.3
±
0.4
h). Blood samples were collected the morning prior to and immediately following the race, and subjects recorded muscle soreness during the week following the race using a 10-point Likert scale (DOMS). Seven plasma cytokines were measured including IL-6, IL-10, IL-8, IL-1ra, granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β). Cytokine changes were compared between NSAID users and nonusers, and correlated with creatine phosphokinase (CPK) and DOMS. Significant increases were measured for all seven cytokines, with the greatest fold increases seen for IL-6 (125×), IL-10 (24×), and G-CSF (12×). CPK was correlated with changes in IL-6, G-CSF, IL-10, IL-1ra, and MCP-1 (
r
=
.49–.68), (
P
<
.001), but not IL-8 or MIP-1β. DOMS averaged 7.1
±
0.3 the day after the race, and 5.0
±
0.3, 2.5
±
0.2, and 1.6
±
0.1 3 days, 5 days, and 7 days post-race, respectively, and each was correlated with CPK (
r
=
.40–.63,
P
<
.001) and changes in IL-6, G-CSF, IL-10, and MCP-1 (
r
=
.28–.77,
P
<
.05). A comparison of NSAID users (72% of athletes) and nonusers showed no differences in CPK or DOMS, but did reveal greater increases in five of seven cytokines in the NSAID users (
P
<
.05). In conclusion, muscle damage in athletes competing in a 160-km race was significantly correlated with post-race DOMS and increases in five of seven cytokines. NSAID users did not experience a reduction in muscle damage or DOMS, but did have higher post-race plasma levels in five of seven cytokines.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Blood Cell Count</subject><subject>Blood Volume - physiology</subject><subject>Body Composition - physiology</subject><subject>Creatine Kinase - blood</subject><subject>Cytokines - blood</subject><subject>Female</subject><subject>Humans</subject><subject>IL-10</subject><subject>IL-1ra</subject><subject>IL-6</subject><subject>IL-8</subject><subject>Lymphocyte Subsets</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscle soreness</subject><subject>Muscle, Skeletal - metabolism</subject><subject>Muscle, Skeletal - pathology</subject><subject>NSAIDs</subject><subject>Physical Endurance - physiology</subject><subject>Running - physiology</subject><issn>0889-1591</issn><issn>1090-2139</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtPwzAURi0EouXxA1iQJ7aEe-PEtcWEKl4SiAVmy7Fvits8IE5B_HtStRIbTN9yvjMcxs4QUgSUl8u0LEOaARQpiBRA7bEpgoYkQ6H32RSU0gkWGifsKMYljKBAdcgmKEEi5nrK5k_r6Gri3jZ2QTxEXod2RZ4PHXffQ7cKLXH3ZtsFRV51dd19hXbBLR8VyarhvXV0wg4qW0c63e0xe729eZnfJ4_Pdw_z68fECZUNiXaCNLmizFwOMp8hSeELpZVXZZ6VQlgNymUFlTqrSm2l9JIqW3hrHTjMxDG72Hrf--5jTXEwTYiO6tq21K2jkSrPMVezf0GciVyrQowgbkHXdzH2VJn3PjS2_zYIZpPYLM2Y2GwSGxBmTDx-znfyddmQ_33smo7A1RagscVnoN5EF6h15ENPbjC-C3_ofwBZPoqO</recordid><startdate>20050901</startdate><enddate>20050901</enddate><creator>Nieman, David C.</creator><creator>Dumke, Charles L.</creator><creator>Henson, Dru A.</creator><creator>McAnulty, Steven R.</creator><creator>Gross, Sarah J.</creator><creator>Lind, Robert H.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TS</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20050901</creationdate><title>Muscle damage is linked to cytokine changes following a 160-km race</title><author>Nieman, David C. ; Dumke, Charles L. ; Henson, Dru A. ; McAnulty, Steven R. ; Gross, Sarah J. ; Lind, Robert H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-9c3e9ec5b2c406471e63d5898d8b42b33a908c25eb92fb9a66d6efa5daac0c123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Blood Cell Count</topic><topic>Blood Volume - physiology</topic><topic>Body Composition - physiology</topic><topic>Creatine Kinase - blood</topic><topic>Cytokines - blood</topic><topic>Female</topic><topic>Humans</topic><topic>IL-10</topic><topic>IL-1ra</topic><topic>IL-6</topic><topic>IL-8</topic><topic>Lymphocyte Subsets</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscle soreness</topic><topic>Muscle, Skeletal - metabolism</topic><topic>Muscle, Skeletal - pathology</topic><topic>NSAIDs</topic><topic>Physical Endurance - physiology</topic><topic>Running - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nieman, David C.</creatorcontrib><creatorcontrib>Dumke, Charles L.</creatorcontrib><creatorcontrib>Henson, Dru A.</creatorcontrib><creatorcontrib>McAnulty, Steven R.</creatorcontrib><creatorcontrib>Gross, Sarah J.</creatorcontrib><creatorcontrib>Lind, Robert H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Physical Education Index</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain, behavior, and immunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nieman, David C.</au><au>Dumke, Charles L.</au><au>Henson, Dru A.</au><au>McAnulty, Steven R.</au><au>Gross, Sarah J.</au><au>Lind, Robert H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Muscle damage is linked to cytokine changes following a 160-km race</atitle><jtitle>Brain, behavior, and immunity</jtitle><addtitle>Brain Behav Immun</addtitle><date>2005-09-01</date><risdate>2005</risdate><volume>19</volume><issue>5</issue><spage>398</spage><epage>403</epage><pages>398-403</pages><issn>0889-1591</issn><eissn>1090-2139</eissn><abstract>Muscle damage and perceived soreness following the 160-km Western States Endurance Run were related to changes in plasma cytokines and use of nonsteroidal anti-inflammatory drugs (NSAIDS). Subjects included 60 ultramarathoners (mean
±
SE, age 45.3
±
1.1 years) who finished the race in under 30
h (26.3
±
0.4
h). Blood samples were collected the morning prior to and immediately following the race, and subjects recorded muscle soreness during the week following the race using a 10-point Likert scale (DOMS). Seven plasma cytokines were measured including IL-6, IL-10, IL-8, IL-1ra, granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β). Cytokine changes were compared between NSAID users and nonusers, and correlated with creatine phosphokinase (CPK) and DOMS. Significant increases were measured for all seven cytokines, with the greatest fold increases seen for IL-6 (125×), IL-10 (24×), and G-CSF (12×). CPK was correlated with changes in IL-6, G-CSF, IL-10, IL-1ra, and MCP-1 (
r
=
.49–.68), (
P
<
.001), but not IL-8 or MIP-1β. DOMS averaged 7.1
±
0.3 the day after the race, and 5.0
±
0.3, 2.5
±
0.2, and 1.6
±
0.1 3 days, 5 days, and 7 days post-race, respectively, and each was correlated with CPK (
r
=
.40–.63,
P
<
.001) and changes in IL-6, G-CSF, IL-10, and MCP-1 (
r
=
.28–.77,
P
<
.05). A comparison of NSAID users (72% of athletes) and nonusers showed no differences in CPK or DOMS, but did reveal greater increases in five of seven cytokines in the NSAID users (
P
<
.05). In conclusion, muscle damage in athletes competing in a 160-km race was significantly correlated with post-race DOMS and increases in five of seven cytokines. NSAID users did not experience a reduction in muscle damage or DOMS, but did have higher post-race plasma levels in five of seven cytokines.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>16061149</pmid><doi>10.1016/j.bbi.2005.03.008</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0889-1591 |
| ispartof | Brain, behavior, and immunity, 2005-09, Vol.19 (5), p.398-403 |
| issn | 0889-1591 1090-2139 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68441487 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Anti-Inflammatory Agents, Non-Steroidal - pharmacology Blood Cell Count Blood Volume - physiology Body Composition - physiology Creatine Kinase - blood Cytokines - blood Female Humans IL-10 IL-1ra IL-6 IL-8 Lymphocyte Subsets Male Middle Aged Muscle soreness Muscle, Skeletal - metabolism Muscle, Skeletal - pathology NSAIDs Physical Endurance - physiology Running - physiology |
| title | Muscle damage is linked to cytokine changes following a 160-km race |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A59%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Muscle%20damage%20is%20linked%20to%20cytokine%20changes%20following%20a%20160-km%20race&rft.jtitle=Brain,%20behavior,%20and%20immunity&rft.au=Nieman,%20David%20C.&rft.date=2005-09-01&rft.volume=19&rft.issue=5&rft.spage=398&rft.epage=403&rft.pages=398-403&rft.issn=0889-1591&rft.eissn=1090-2139&rft_id=info:doi/10.1016/j.bbi.2005.03.008&rft_dat=%3Cproquest_cross%3E68441487%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17349853&rft_id=info:pmid/16061149&rft_els_id=S088915910500053X&rfr_iscdi=true |